Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Abstract Text:

Hiroshi Takatani,Hiroshi Soda,Yoichi Nakamura,Akitoshi Kinoshita,Masaaki Fukuda,Seiji Nagashima,Minoru Fukuda,Yoshifumi Soejima,Hirofumi Nakano,Mikio Oka,Shigeru Kohno, ,

BACKGROUND: Irinotecan and gemcitabine are effective against non-small cell lung cancer. We conducted a phase I study of the combined use of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer to determine dose-limiting toxicities and maximum tolerated dose. METHODS: Patients were treated with irinotecan followed by gemcitabine on days 1 and 8 every 3 weeks. Gemcitabine dose was fixed at 1000 mg/m2, and irinotecan dose was increased from 60 mg/m2. RESULTS: A total of 16 patients was enrolled. Maximum tolerated dose of irinotecan was determined up to level 3 (irinotecan 100 mg/m2). In Japan, the maximum approved weekly dose of irinotecan is 100 mg/m2, so this was the dose that was used. Only very mild hematological and non-hematological toxicities were noted. CONCLUSION: Use of 100 mg/m2 irinotecan followed by 1000 mg/m2 gemcitabine on days 1 and 8 every 3 weeks warrants a phase II study.

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Publishing Authors By Initials

H Takatani,H Soda,Y Nakamura,A Kinoshita,M Fukuda,S Nagashima,M Fukuda,Y Soejima,H Nakano,M Oka,S Kohno, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Japanese journal of clinical oncology

VOLUME: 37

Page Numbers: 353-7

Journal Abbreviation: Jpn. J. Clin. Oncol.

ISSN: 1465-3621

DAY: 29

MONTH: May

YEAR: 2007

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 313225

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.

AFFILIATION: Department of Internal Medicine, Nagasaki Municipal Hospital, Nagasaki, Japan.

Country: Japan

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jpn J Clin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer Related Publications

• Acute hepatitis E of a man who consumed wild boar meat prior to the onset of illness in Nagasaki, Japan.
• Association of uncoupling protein-2 expression with increased reactive oxygen species in residual myocardium of the enlarged left ventricle after myocardial infarction.
• Bone morphogenetic protein-2 promotes survival and differentiation of striatal GABAergic neurons in the absence of glial cell proliferation.
• Cardiac function as assessed by echocardiography in the oldest old >/= 90 years of age.
• Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
• Comparison of the grade evaluated by "Liver damage" of Liver Cancer Study Group of Japan and Child-Pugh classification in patients with hepatocellular carcinoma.
• Crystallization and preliminary crystallographic analysis of an octaketide-producing plant type III polyketide synthase.
• Detection of new antigenic proteins in Japanese cedar pollen.
• Differential expression of the glycosylated forms of MUC1 during lung development.
• Effects of acetaldehyde on human airway constriction and inflammation.
• Expression of aldosterone synthase gene in IgA nephropathy (IgAN).
• Granulocyte colony-stimulating factor facilitates the angiogenesis induced by ultrasonic microbubble destruction.
• How transmembrane proteins sense endoplasmic reticulum stress.
• In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
• Intracellular balance of oxidative stress and cytoprotective molecules in damaged interlobular bile ducts in autoimmune hepatitis and primary biliary cirrhosis: In situ detection of 8-hydroxydeoxyguanosine and glutathione-S-transferase-pi.
• Latent cardiac dysfunction as assessed by echocardiography in bed-bound patients following cerebrovascular accidents.
• Low-dose oral methotrexate for the management of childhood Cogan's syndrome: a case report.
• Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
• Recent advances in understanding the unfolded protein response.
• Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis.
• Signal transducer and activator of transcription 3 involvement in the development of renal interstitial fibrosis after unilateral ureteral obstruction.
• Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2.
• Structural insight into chain-length control and product specificity of pentaketide chromone synthase from Aloe arborescens.
• Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47.
• Telephone counseling of athletes abusing anabolic-androgenic steroids.
• Transgenic mice expressing a fully nontoxic diphtheria toxin mutant, not CRM197 mutant, acquire immune tolerance against diphtheria toxin.
• Wireless Vital Sign Monitoring using Ultra Wideband-Based Personal Area Networks.
• [A case of idiopathic chylothorax successfully treated with surgical ligation of thoracic ducts]
• [A case of mycoplasmal pneumonia with bronchiolitis treated with steroids]
• [Nontuberculous mycobacterial infections involving solitary pulmonary nodules]